REFINE: A Randomized Trial Comparing Cyclosporine A and Tacrolimus on Fibrosis After Liver Transplantation for Hepatitis C
β Scribed by Levy, G.; Villamil, F. G.; Nevens, F.; Metselaar, H. J.; Clavien, P.-A.; Klintmalm, G.; Jones, R.; Migliaccio, M.; Prestele, H.; Orsenigo, R.
- Book ID
- 121831531
- Publisher
- John Wiley and Sons
- Year
- 2014
- Tongue
- English
- Weight
- 247 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1600-6135
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Hepatitis C virus (HCV)-induced cirrhosis is the commonest indication for orthotopic liver transplantation, but HCV recurrence is nearly universal and may worsen patient / graft outcomes. The frequency and severity of HCV recurrence has apparently increased in recent years, raising concern about a p
Hepatitis C virus (HCV) infection usually recurs after orthotopic liver transplantation (OLT), and most patients develop graft damage. This study compared the efficacy of interferon alfa (IFN-β£) and ribavirin monotherapies in liver transplant recipients with chronic hepatitis C in the graft. Thirty
Less potent immunosuppression is considered to reduce the severity of hepatitis C virus (HCV) recurrence after liver transplantation. An optimal regimen is unknown. We evaluated tacrolimus monotherapy versus triple therapy in a randomized trial of 103 first transplants for HCV cirrhosis. One hundred